ADAMTS

AcronymDefinition
ADAMTSA Disintegrin-Like and Metalloproteinase with Thrombospondin
References in periodicals archive ?
Large multimers are assembled in a normal fashion but straight after secretion they bind spontaneously to platelets and are cleaved by ADAMTS 13, a disintegrin-like and metalloprotease domain with thrombosponding type 1 motifs (12).
A disintegrin-like and metalloprotease (reprolysin type) with thrombospondin type 1 motifs: the ADAMTS family.
ADAMTS proteinases: a multi-domain, multi-functional family with roles in extracellular matrix turnover and arthritis.
6 Auto antibodies against ADAMTS13 in acquired TTP and mutations in ADAMTS 13 gene in congenital TTP cause its deficiency.
TTP is associated with an acquired or an inherited deficiency of the von Willebrand factor - cleaving protease ADAMTS 13.
Cloning, expression analysis, and structural characterization of seven novel human ADAMTSs, a family of metalloproteinases with disintegrin and thrombospondin-1 domains.
El factor transformante del crecimiento [beta] (TGF-[beta], por la sigla en ingles de transforming growth factor-[beta]) es una sustancia que se encuentra normalmente en concentraciones bajas; se la requiere para la sintesis de matriz y protege el catabolismo de esta al contrarrestar los efectos daninos de sustancias proinflamatorias que activan la MMP-1 y la MMP-9; paradojicamente, tambien posee efectos proinflamatorios y puede activar la MMP-13 y agrecanasas como catepsina B y ADAMTS (por la sigla en ingles de a disintegrin and a metallproteinase with thrombospondin motifs) (6,30).
George (2007) explains that ADAMTS 13 is an acronym for a disintegrin and metalloprotease with thrombospondin repeats that acts as a Von Willebrand Factor, VWF-cleaving protease.
Su proposito es administrar elementos deficitarios en el plasma como en pacientes con purpura trombocitopenica trombotica en la que el ADAMTS 13 (quien evita la excesiva agregacion plaquetaria) es deficitario.
27,28) Several groups have looked at direct inhibition of MMPs in both OA and RA, and these agents have been associated with adverse musculoskeletal events, such as bursitis and fibrosing contractures, when used in oncology trials (29); still, there is hope that more focused MMP inhibitors that are specific for MMP-13 and ADAMTS will be more successful.